BF 389
Alternative Names: Biofor 389Latest Information Update: 01 Jun 1999
At a glance
- Originator Scherer Healthcare
- Class Analgesics; Anti-inflammatories; Antipsoriatics; Antirheumatics; Oxazines
- Mechanism of Action Cyclooxygenase inhibitors; Lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 01 Jun 1999 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
- 09 Jul 1998 Biofor is now part of Scherer Healthcare
- 15 Aug 1995 Phase-I clinical trials for Rheumatic disorders in USA (Unknown route)